Literature DB >> 23950590

Inhibitory effect of antidepressants on B16F10 melanoma tumor growth.

Beata Grygier1, Beatriz Arteta, Marta Kubera, Agnieszka Basta-Kaim, Bogusława Budziszewska, Monika Leśkiewicz, Katarzyna Curzytek, Weronika Duda, Władysław Lasoń, Michael Maes.   

Abstract

BACKGROUND: Antidepressant drugs, like fluoxetine, a selective serotonin reuptake inhibitor, desipramine, a nonselective noradrenaline reuptake inhibitor, and mirtazapine, an antagonist of noradrenaline α2 auto- and heteroreceptors, are widely used for the treatment of depressive symptoms in cancer patients. Since these antidepressants have different activities targeting the immune system, they might also modulate tumor growth in cancer patients.
METHODS: In the present study, we investigated the effects of administration of antidepressant drugs: fluoxetine, desipramine and mirtazapine on B16F10 melanoma tumor growth. These drugs were administered intraperitoneally (ip) for 17 days after subcutaneous injection of B16F10 melanoma cells to male C57BL/6J mice.
RESULTS: Fluoxetine significantly inhibited melanoma solid tumor growth and desipramine tended to decrease this parameter whereas mirtazapine had no effect.
CONCLUSION: The inhibitory effect of fluoxetine on melanoma growth was associated with an increased mitogen-induced T cell proliferation which may at least partly participate in the mechanism of the antitumor effect of this antidepressant. It appears that the inhibitory effect of fluoxetine on tumor growth is not related with changes in cytokine levels except for IL-10.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23950590     DOI: 10.1016/s1734-1140(13)71045-4

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  10 in total

Review 1.  Neurotransmitters: emerging targets in cancer.

Authors:  Shu-Heng Jiang; Li-Peng Hu; Xu Wang; Jun Li; Zhi-Gang Zhang
Journal:  Oncogene       Date:  2019-09-16       Impact factor: 9.867

Review 2.  Stress and cancer: mechanisms, significance and future directions.

Authors:  Anabel Eckerling; Itay Ricon-Becker; Liat Sorski; Elad Sandbank; Shamgar Ben-Eliyahu
Journal:  Nat Rev Cancer       Date:  2021-09-10       Impact factor: 60.716

Review 3.  Immunomodulatory effects mediated by serotonin.

Authors:  Rodrigo Arreola; Enrique Becerril-Villanueva; Carlos Cruz-Fuentes; Marco Antonio Velasco-Velázquez; María Eugenia Garcés-Alvarez; Gabriela Hurtado-Alvarado; Saray Quintero-Fabian; Lenin Pavón
Journal:  J Immunol Res       Date:  2015-04-19       Impact factor: 4.818

4.  The antidepressant fluoxetine induces necrosis by energy depletion and mitochondrial calcium overload.

Authors:  Emilie Charles; Mehdi Hammadi; Philippe Kischel; Vanessa Delcroix; Nicolas Demaurex; Cyril Castelbou; Anne-Marie Vacher; Anne Devin; Thomas Ducret; Paula Nunes; Pierre Vacher
Journal:  Oncotarget       Date:  2017-01-10

5.  Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case-control study.

Authors:  Leon Alexander Mclaren Berge; Bettina Kulle Andreassen; Jo Steinson Stenehjem; Inger Kristin Larsen; Kari Furu; Asta Juzeniene; Ingrid Roscher; Trond Heir; Adele Green; Marit Bragelien Veierød; Trude Eid Robsahm
Journal:  BMJ Open       Date:  2019-02-20       Impact factor: 2.692

6.  HTR1A Inhibits the Progression of Triple-Negative Breast Cancer via TGF-β Canonical and Noncanonical Pathways.

Authors:  Qiqi Liu; Hefen Sun; Yang Liu; Xuan Li; Baojin Xu; Liangdong Li; Wei Jin
Journal:  Adv Sci (Weinh)       Date:  2022-02-24       Impact factor: 17.521

Review 7.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

8.  Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry-Based Case-Control Study.

Authors:  Leon Alexander Mclaren Berge; Bettina Kulle Andreassen; Jo S Stenehjem; Trond Heir; Kari Furu; Asta Juzeniene; Ingrid Roscher; Inger Kristin Larsen; Adele C Green; Marit B Veierød; Trude E Robsahm
Journal:  Clin Epidemiol       Date:  2020-02-21       Impact factor: 4.790

Review 9.  Modifications of Plasma Membrane Organization in Cancer Cells for Targeted Therapy.

Authors:  Anna Choromańska; Agnieszka Chwiłkowska; Julita Kulbacka; Dagmara Baczyńska; Nina Rembiałkowska; Anna Szewczyk; Olga Michel; Agnieszka Gajewska-Naryniecka; Dawid Przystupski; Jolanta Saczko
Journal:  Molecules       Date:  2021-03-25       Impact factor: 4.411

10.  Melanization as unfavorable factor in amelanotic melanoma cell biology.

Authors:  A Skoniecka; M Cichorek; A Tyminska; I Pelikant-Malecka; J Dziewiatkowski
Journal:  Protoplasma       Date:  2021-01-27       Impact factor: 3.356

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.